Sander Beate, Bauch Chris, Fisman David N, Fowler R, Kwong Jeffrey C, McGeer Allison, Zivkovic Gojovic Marija, Krahn Murray
Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; University of Guelph; Dalla Lana School of Public Health, University of Toronto; Sunnybrook Hospital, The University of Toronto; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto; Toronto Health Economics and Technology Assessment Collaborative(THETA) and University of Toronto.
PLoS Curr. 2009 Dec 17;1:RRN1137. doi: 10.1371/currents.rrn1137.
This work contributes informed estimates to the current debate about the pandemic (H1N1) 2009 mass immunization program's economic merits. We performed a cost-utility analysis of the (H1N1) 2009 mass immunization program in Ontario, Canada's most populous province. The analysis is based on a simulation model of a pandemic (H1N1) 2009 outbreak, surveillance data, and administrative data. We consider no immunization versus mass immunization reaching 30% of the population. Immunization program costs are expected to be $118 million in Ontario. Our analysis indicates this program will reduce influenza cases by 50%, preventing 35 deaths, and cutting treatment costs in half. A pandemic (H1N1) 2009 immunization program is likely to be highly cost-effective.
这项工作为当前关于2009年甲型H1N1流感大流行大规模免疫计划经济价值的辩论提供了有依据的评估。我们对加拿大人口最多的省份安大略省的2009年甲型H1N1流感大规模免疫计划进行了成本效益分析。该分析基于2009年甲型H1N1流感大流行爆发的模拟模型、监测数据和行政数据。我们比较了不进行免疫接种与大规模免疫接种覆盖30%人口这两种情况。预计安大略省的免疫计划成本为1.18亿美元。我们的分析表明，该计划将使流感病例减少50%，预防35例死亡，并将治疗成本减半。2009年甲型H1N1流感免疫计划可能具有很高的成本效益。
